Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Deferred Revenue (2016 - 2024)

Cartesian Therapeutics (RNAC) has disclosed Current Deferred Revenue for 10 consecutive years, with $412000.0 as the latest value for Q1 2024.

  • On a quarterly basis, Current Deferred Revenue fell 95.77% to $412000.0 in Q1 2024 year-over-year; TTM through Mar 2024 was $412000.0, a 95.77% decrease, with the full-year FY2023 number at $2.3 million, up 289.71% from a year prior.
  • Current Deferred Revenue was $412000.0 for Q1 2024 at Cartesian Therapeutics, down from $2.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $115.8 million in Q3 2020 to a low of $412000.0 in Q1 2024.
  • A 5-year average of $33.6 million and a median of $9.2 million in 2021 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 11223.46% in 2020, then crashed 95.77% in 2024.
  • Cartesian Therapeutics' Current Deferred Revenue stood at $72.0 million in 2020, then tumbled by 87.23% to $9.2 million in 2021, then tumbled by 93.55% to $593000.0 in 2022, then skyrocketed by 289.71% to $2.3 million in 2023, then tumbled by 82.17% to $412000.0 in 2024.
  • Per Business Quant, the three most recent readings for RNAC's Current Deferred Revenue are $412000.0 (Q1 2024), $2.3 million (Q4 2023), and $8.1 million (Q3 2023).